Focus: Santen is a newly-established (2023) ophthalmology-focused biotechnology company headquartered in Emeryville, CA with an extensive clinical pipeline across dry eye, glaucoma, retinal diseases, and corneal conditions.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Cooling — net -5 jobs in 30d
21 added, 26 removed. Slower than typical.
Santen is a high-risk, high-opportunity play for those willing to build something from the ground up in ophthalmology; best suited for early-career or mission-driven professionals comfortable with execution uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Legacy antibiotic asset approaching patent expiration with minimal differentiation.
Help build intelligence for Santen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Santen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Mature antibiotic with waning market protection and generic competition.
Allergy indication asset facing patent cliff with commodity-like competitive landscape.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo